Anti-Idiotype Antibody Development

Around 70% of ABclonal’s clients have therapeutic goals for their monoclonal antibody development projects. The effects of the therapeutic lead candidates can be evaluated using antibodies recognizing unique variable regions in each candidate, known as anti-idiotype (anti-ID) antibodies. Anti-ID antibodies can be used to identify, neutralize, block, and assess drug-to-analyte binding properties on the target therapeutic antibody.

Useful in anti-drug antibody (ADA) and pharmacokinetic (PK) analysis, anti-idiotype antibodies help provide information about how the drug is absorbed, distributed, metabolized, and eliminated in the patient’s body. These assays and studies help optimize the antibody-based drugs to ensure patients receive safe and effective treatments.

With over 90% success in generating the desired responses in anti-ID antibodies, ABclonal prepares you to successfully detect, identify, and analyze therapeutic drugs to support your upcoming preclinical and downstream clinical trials.

Anti-ID Antibody strategy

Measure free therapeutic antibody in circulation

Measure total drug levels

Detect bound drug levels only

Trusted Experience

Proprietary SMab™ platform rapidly identifies blocking and non-blocking antibodies.

Single immunization for both polyclonal and monoclonal anti-ID antibody discovery with high diversity.

Professional hands-on project design and management with fast turnaround time.

800 anti-ID antibodies delivered against a wide range of targets.

Case Study - Anti-ID Antibodies Against COVID-19 Fab




  • Bleed titer and blocking measured with ELISA and additional assays as requested
  • Antigen affinity purification of terminal bleed from immunized rabbits if desired


Splenocyte collection
& single B cell sorting

  • SMab™ antigen-specific B cell sorting and culture
  • High throughput screening for positive clones


VH/VL cloning &
LEM construction

  • Gene amplification from selected positive B cells
  • Linear expression module (LEM) construction and transfection
  • Additional screening assays as requested


Expression plasmid
construction &
antibody production

  • Subclone antibody genes into mammalian expression vector from selected clones
  • Small scale expression and protein A/G purification for initial testing
  • QC via assay validation
  • Final delivery

Note: Timeline is based on delivery of 20 LEMs and 5 rabbit antibodies.